Adoptive T-Cell Therapy in Melanoma: How This Will Impact Surgical Practice and the Role of Surgeons

Area of Science:

• Oncology
• Surgical Oncology
• Immunotherapy

Background:

• Metastatic melanoma management involves surgery in select cases.
• The role of surgery for metastatic melanoma is evolving with the advent of immune checkpoint blockade therapies.
• Adoptive cell therapies (e.g., tumor-infiltrating lymphocytes, chimeric antigen receptor T cells) are emerging as treatment options.

Purpose of the Study:

• To delineate the role of surgery for metastatic melanoma in the context of current immunotherapies.
• To highlight the importance of surgical techniques for obtaining specific immune cells and antigens for cell-based therapies.
• To emphasize the need for surgeons to be proficient in tissue procurement for personalized cancer treatments.

Main Methods:

• Review of current literature on surgical management of metastatic melanoma.
• Analysis of the integration of surgical procedures with adoptive cell therapy protocols.
• Discussion of essential surgical techniques for tissue procurement and delivery.

Main Results:

• Surgery is crucial for obtaining tumor-specific immune cells and antigens required for personalized cell-based therapies.
• Metastasectomy is often a prerequisite for generating effective adoptive cell products.
• Surgical expertise is vital for successful preoperative planning and postoperative recovery in patients undergoing these treatments.

Conclusions:

• Surgical intervention remains important in managing metastatic melanoma, particularly for enabling advanced immunotherapies.
• Surgeons require specialized knowledge of tissue procurement techniques to support the development of personalized cell-based cancer treatments.
• Optimizing surgical approaches is essential for maximizing the efficacy of adoptive cell therapies in melanoma patients.